Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 41
- Registration Number
- NCT00935220
- Locations
- πΊπΈ
1218.55.0004 Boehringer Ingelheim Investigational Site, Miami, Florida, United States
πΊπΈ1218.55.0008 Boehringer Ingelheim Investigational Site, Deland, Florida, United States
πΊπΈ1218.55.0006 Boehringer Ingelheim Investigational Site, Cypress, California, United States
An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.
- Conditions
- HIV Infections
- First Posted Date
- 2009-07-07
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT00933205
- Locations
- π§πͺ
1182.16.3202 Boehringer Ingelheim Investigational Site, Antwerpen, Belgium
π§πͺ1182.16.3203 Boehringer Ingelheim Investigational Site, Brussel, Belgium
π§πͺ1182.16.3204 Boehringer Ingelheim Investigational Site, Gent, Belgium
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2009-07-03
- Last Posted Date
- 2016-02-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 100
- Registration Number
- NCT00932646
- Locations
- πΊπΈ
1222.25.25009 Boehringer Ingelheim Investigational Site, Jasper, Alabama, United States
πΊπΈ1222.25.25010 Boehringer Ingelheim Investigational Site, Austell, Georgia, United States
πΊπΈ1222.25.25008 Boehringer Ingelheim Investigational Site, Albuquerque, New Mexico, United States
(Hyoscine Butylbromide) for Abdominal Pain Associated With Cramping on Demand Basis
- Conditions
- Abdominal Pain
- Interventions
- Drug: PlaceboDrug: HBB 20 mg
- First Posted Date
- 2009-07-03
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 197
- Registration Number
- NCT00932737
- Locations
- πΊπΈ
202.839.01003 Boehringer Ingelheim Investigational Site, Hollywood, Florida, United States
πΊπΈ202.839.01005 Boehringer Ingelheim Investigational Site, Indianapolis, Indiana, United States
πΊπΈ202.839.01009 Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2014-07-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 99
- Registration Number
- NCT00931385
- Locations
- πΊπΈ
1222.24.24009 Boehringer Ingelheim Investigational Site, Overland Park, Kansas, United States
πΊπΈ1222.24.24002 Boehringer Ingelheim Investigational Site, Cincinnati, Ohio, United States
πΊπΈ1222.24.24010 Boehringer Ingelheim Investigational Site, Oklahoma City, Oklahoma, United States
Actuation Indicator Trial in Patients With COPD
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Device: Ipratropium bromide
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2014-07-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 142
- Registration Number
- NCT00928746
- Locations
- πΊπΈ
244.2507.0103 Boehringer Ingelheim Investigational Site, Spartanburg, South Carolina, United States
πΊπΈ244.2507.0104 Boehringer Ingelheim Investigational Site, Greenville, South Carolina, United States
πΊπΈ244.2507.0101 Boehringer Ingelheim Investigational Site, Union, South Carolina, United States
Efficacy (Bronchoprotection) and Safety of Orally Inhaled BI 1744 CL in Patients With Intermittent Asthma
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2014-07-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT00928668
- Locations
- π¨π¦
1222.4.103 UBC - Respiratory Medicine, Vancouver, British Columbia, Canada
π¨π¦1222.4.102, Saskatoon, Saskatchewan, Canada
π¨π¦1222.4.104 Department of Medicine, Health Sciences Centre, Hamilton, Ontario, Canada
Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension
- First Posted Date
- 2009-06-23
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 894
- Registration Number
- NCT00926289
- Locations
- πΊπΈ
502.550.01007 Boehringer Ingelheim Investigational Site, Greensboro, North Carolina, United States
π¨π³502.550.86002 Boehringer Ingelheim Investigational Site, Shanghai, China
π¨π³502.550.86007 Boehringer Ingelheim Investigational Site, Tianjin, China
Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 567
- Registration Number
- NCT00915772
- Locations
- π¨π¦
1218.52.11003 Boehringer Ingelheim Investigational Site, Edmonton, Alberta, Canada
π¨π¦1218.52.11002 Boehringer Ingelheim Investigational Site, Red Deer, Alberta, Canada
ππ·1218.52.38502 Boehringer Ingelheim Investigational Site, Karlovac, Croatia
Telmisartan 80mg+Hydrochlorothiazide (HCTZ) 25 mg in Hypertension: an Observational Study
- Conditions
- Hypertension
- First Posted Date
- 2009-05-27
- Last Posted Date
- 2014-06-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2411
- Registration Number
- NCT00909038
- Locations
- π«π·
Boehringer Ingelheim Investigator site 359, La Tour Du Crieu, France
π«π·Boehringer Ingelheim Investigator site 360, La Turballe, France
π«π·Boehringer Ingelheim Investigator site 361, La Varenne St Hilaire, France